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Lymphocytic choriomeningitis (LCM) t virus takes its name from the acutely fatal 
central nervous system (CNS)  disease  which was described by Armstrong and Lillie 
in their original isolation and characterization of this agent 0). Subsequent work has 
established that LCM  virus will regularly produce infection in adult mice but the 
occurrence of fatal choriomeningitis is influenced by the interaction of variables in- 
cluding route of inoculation (2, 3), strain of virus (4, 5), and age and strain of mouse 
(6-9). Brains of affected mice show severe infection of choroid plexus, ependyma, and 
leptomeninges (10,  11), and animals die with a characteristic syndrome (1, 2, 4) in- 
cluding a prominent convulsive diathesis, the exact mechanism of which has not been 
elucidated. 
Evidence that  acute  choriomeningitis has  an  immunopathological basis  derives 
from two sources:  (a)  the noncytocidal nature of LCM  infection of cells in vivo as 
indicated by the ability of mice, infected (luring gestation or within 24 hr of birth, 
to develop and reproduce in spite of a widespread systemic infection (12, 13), and (b) 
the ability of immunosuppressive treatments to convert a potentially fatal infection 
into a chronic carrier state compatible with long-term survival, in spite of high virus 
titers in the brain or other tissues (14-16). 
The  present  study  reports  the  use  of  cyclophosphamide  (CY)  as  a  con- 
venient and reliable method of converting potentially lethal choriomeningitis 
in adult mice into a nonfatal carrier infection, together with n description of the 
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progression  of  infection  which  occurs  in  the  CNS  during  persistence  of  the 
carrier state.  A  comparison  is then made with  the carrier state  established  by 
virus inoculation of neonatal mice, in which the distribution  of virus infection 
in  the  CNS  differs  both  qualitatively  and  quantitatively.  Most  importantly, 
these  observations  are  essential  for interpretation  of the  different  response  of 
these two types of carriers to transferred  immune lymphoid cells, the subject of 
the next paper  in this series. A  preliminary overview of these studies  has been 
presented in a recent review (17). 
Materials and Methods 
Animals.--Weanling and  adult  male  (10-12-wk-old)  BALB/c mice obtained  from Flow 
Laboratories,  Dublin,  Va., were used for experimental infections, and  adult  Swiss  Webster 
mice from Microbiological Associates,  Walkersville, Md., were used for virus titrations. 
Drug.--CY  (Cytoxan, Mead Johnson & Co., Evansville, Ind.) was diluted to give a dose of 
150 mg/kg in 0.5 ml which was injected intraperitoneally. This dose produces toxic deaths in 
no more than  10% of mice weighing over 20 g, while the fatality rate is greater in younger 
mice. 
Virus.--The E-350 strain of LCM virus was provided by Dr. Frederick Murphy  (16) who 
originally obtained it from the American Type Culture Collection (VR 134). Stock virus was 
prepared by intracerebral  (i.c.)  inoculation of adult mice, and brains were harvested 6 days 
later. A clarified  20~o homogenate in buffered saline was stored at  --70°C. This preparation 
had an adult mouse i.c.  titer of 106 LD~0/0.03 ml, and was used at a  10  -3 dilution  to give a 
standard inoculum of about 1000 Ia)50. 
Virus Titrations.--Anesthetized mice were bled from the heart or the retroorbital venous 
plexus; blood was diluted into 4 volumes of cold phosphate-buffered saline (PBS) containing 
0.75%  bovine plasma  albumin  with heparin,  and  plasma  was  obtained  by centrifugation. 
Brains were removed from perfused mice, homogenized, and prepared as clarified 20o-/0 suspen- 
sions in PBS.  Decimal dilutions of plasma  or brain homogenates were titrated i.c.  in adult 
Swiss mice. Titers were calculated by the K/irber method (18) and expressed as the LD 5O/0.03 
ml or 0.03 g. 
Immunofluorescent Staining.--Brains from saline-perfused mice were cut in 8-# parasagittal 
sections in a cryostat, fixed in acetone for 5 rain, and stored at --20°C. Fluorescein-conjugated 
LCM-immune serum was obtained from Dr. Roger Wilsnack  (10), and used with an Evans 
blue counterstain as previously described  (19). The specificity of this reagent was indicated 
by its failure to stain  uninfected brains and  by an  approximate correlation of numbers  of 
stainable cells with titer of infectious virus. CNS areas were graded for fluorescence according 
to a semiquantitative scale: trace, less than 1% of cells fluorescing; 1, 1-25%; 2, 25-50%; 3, 
50-75%; and 4, 75-100%. 
Light Microscopy.--Mice were perfused with isotonic saline followed by 1% acetic acid in 
10% formalin. Paraffin sections were cut at 10 # and stained with hematoxylin and  erythrosin. 
Complement-Fixing (CF) Antibody.--Sera were tested for CF antibody in a microtiter test 
(20),  using LCM  antigen at  an  optimum  dilution  of  1:40  (obtained  from Microbiological 
Associates, Inc., Bethesda,  Md.)  and  5 CHs0.  Any anticomplementary activity present in 
sera was successfully  removed by incubating equal volumes of serum, saline,  and fresh oval- 
bumin for 30 rain at 45°C. 
RESULTS 
Drug-Induced Adult LCM Carriers 
Protection from A cute LCM Disease by Cyclophosphamide.--All adult BALB/c 
mice  inoculated  i.c.  with  1000  LI)50  of  LCM  virus  developed  acute  LCM 862  PATHOGENESIS  OF  LYMPHOCYTIC  CHORIO~[ENINGITIS,  I 
within 6  8  day's. Fig.  1 illustrates survival after a single intraperitoneal  (i.p.) 
dose of CY, 150 mg/kg, given 3 day's after LCM virus. More than 90% of mice 
were spared from acute LCM. After recovering  from  the  temporary  toxicity 
caused by the drug (weight and hair loss), they remained asymptomatic for at 
least 6 months. A  small number of mice (less than 10%) which received LCM 
followed by CY  developed a  fatal convulsive diathesis  from  1 to  2 wk  after 
infection. These animals appeared to have "escaped" from the immunosuppres- 
sire  effect of CY,  and  the  presence of  acute  choriomeningitis  was  confirmed 
histologically'. There were no deaths in mice which received CY only. 
Timing of Immunosuppression.--To  permanently protect the greatest number 
of mice from acutely fatal LCM disease, the most propitious time to give CY 
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FIG. 1. Survival after i.c. inoculation of 1000 LD50 of I,  CM virus in 12-wk-old BALB/'c 
mice, and the effect of a single i.p. inoculation of CY, 150 mg/kg, 3 days after virus. 
was  3-5  day's after virus.  If drug  administration  was  delayed until  6-7  days 
after virus inoculation all mice died and survival time was not prolonged. 
If a single CY dose of 150 mg/kg on day 3 was followed by doses of 50 mg/kg 
on days 8, 13, 18, and 23, effective immunosuppression occurred in all mice, and 
there were no deaths up to 21 days after infection. However, many mice failed 
to survive this drug schedule,  and died 217>25 days after infection,  so that 40 
day survival was less than 50 9~. 
Neuropathological Observaliom.--Mice given virus only were sacrificed daily 
to  follow  the  development  of  CNS  lesions.  Pathologic  changes,  except  for 
infrequent  mild vasculitis,  were confirmed t9  choroid plexus,  ependyma, and 
meninges.  The  most  severe  inflammation  was  regularly  seen  in  the  choroid 
plexus of all ventricles. It first appeared about 48 hr before death (4 or 5 days 
after infection) in the area of the tenia choroidea and then spread to the rest of 
the  plexus. The early infiltrate was composed primarily- of large inononuclear 
cells with fine chromatin granules and nuclear indentation.  In addition,  a few 
potymorphonuclear leukocvtes were seen.  2 days later,  in  moribund mice  the FIG. 2.  (a) Choroid plexus of fourth ventricle from a mouse inoculated i.c. with LCM virus 
and perfused when moribund 6 days later. Hematoxylin and  erythrosin.  X  225.  (b)  Similar 
view of choroid plexus from a mouse inoculated with virus, given CY (150 mg/kg) 3 days later, 
and asymptomatic when perfused 10 days after virus injection.  X  225. 
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inflammatory lesion (Fig. 2 a) was composed mostly of small and large mono- 
nuclear cells, but polymorphonuclear leukocytes were more common. 
Adult mice receiving LCM virus followed by CY did not develop histologic 
evidence of  acute choriomeningitis (Fig. 2 b)  except for the less than 10 %  of 
mice which died 7-14 days later of acute LC2d disease.  CNS  lesions in these 
animals were similar to those in mice receiving virus only. 
Virologic Studies.--The titers of virus in brain and blood obtained at serial 
intervals after i.c. inoculation of  adult mice are shown in Table I. The brain 
TABLE I 
Titers of Virus in Brain  and Blood of Adult Male BALB/c Mice Inoculated [ntracerebrally 
with LCM Virus with and without CY* 
Days after 
Specimen  C¥  infection  No. of pools 
Logt~ titer per 0.03 ml or 0.03 g 
Median  R~mge 
Brain 
Plasma 
--  1  1  <0.5 
--  3  1  5.0  -- 
--  5  3  5.7  5.3-6.0 
--  6  8  5.8  5.7-6.2 
--  7  2  5.6  5.2-6.0 
+  5-15  9  6.0  5.3-6.9 
+  17-32  8  5.0  4.6-6.0 
+  131-220  2  3.0  2.8-3.3 
--  1  1  <0.5  -- 
-  3  4  0.6  <0.5--0.7 
--  5  4  0.7  <0.5-0.8 
--  6  3  0.8  0.8-1.3 
--  7  3  <0.5  <0.5-<0.5 
+  7  2  1.1  0.8-1.5 
+  9-15  4  2.4  1.8-3.2 
+  17-32  3  1.5  1.0-3.2 
+  131-220  2  3.9  3.8-4.0 
* Specimens from two mice were combined for 
CY on days 3 or 5 or multiple doses on days 3, 8, 
were similar regardless of CY schedule. 
each pool. Mice received a single dose of 
13, 18, and 23 after infection. Virus titers 
was heavily infected by day 3 and peak virus titers were reached within 5 days 
after inoculation. Minimal viremia was present from days 3 through 6 but had 
disappeared by day 7 in mice which received virus only. 
In CY-induced LCM  carrier mice,  virus titers  in the  brain persisted  at  a 
level similar to that seen in the moribund animal for at least 30 days after in- 
fection, and a  small number of specimens examined up to  7 months after in- 
fection yielded considerable virus titers. Viremia was regularly present in im- 
munosuppressed mice in plasmas obtained from 7 days to 1 yr after infection, 
at a higher titer than the trace levels seen in nonsuppressed animals. 
CF  Antibody.--No  antibody was  found in the  sera  of mice dying of  acute GILDEN,  COLE,  MONJAN,  AND  NATHANSON  865 
LCM,  or those of drug-induced virus carriers  (tested up to 30 days after initia- 
tion of infection), or of neonatal  carriers  (tested up to 45  days after infection). 
Distribution  of  Virus  in  the Brain.--Table  II  compares  the  distribution  of 
viral antigen in different areas of the brains from mice inoculated i.c. with LCM 
virus and examined as adults by direct immunofluorescent staining. 
TABLE  II 
Distribution and Severity of Infection in the CNS of Mice Inoculated Intracerebrally with LCM 
Virus* 
CNS area 
LCM only  LCM +  CY  Neonatal LCM 
PID  PID  PID  PID  PID 
6-8  7-12  23-32  7  56-75 
Choroid plexus and ependyma  4:~  3  3  3  1 
Leptomeninges  t  t  t  2  t 
Endothelium  0  0  0  t  t 
Cerebral cortex  0  t  t  2  2 
Olfactory area  t  1  1  3  3 
Hippocampus, pyramidal cells  0  0  t  2  2 
Hippocampus, dentate gyms  0  0  t  3  3 
Lenticulostriate area  0  t  1  2  2 
Subventricular plate  3 
Diencephalon  t  t  1  2  2 
Midbrain  0  0  t  2  1 
Pons and medulla 
Cerebellum, Purkinje cells 
Cerebellum, granule cells 
Cerebellum, molecular layer 
Cerebellum, white matter 
0  0  t  2  1 
0  0  0  t  2 
0  0  t  3  t 
0  t  2  t 
0  0  t  t  t 
* LCM only: inoculated as adults. LCM +  CY: inoculated as adults and given CY,  150 
mg/kg, on day 3 after infection (PID 3).  Neonatal LCM: inoculated within 24  hr of birth. 
PID: days from infection to sacrifice.  Choroid plexus represents composite for  lateral  and 
fourth ventricles. Olfactory area includes olfactory bulb and paleocortex. 
Proportion  of cells infected based  on immunofluorescent staining:  t,  less  than  1%;  1, 
1-25%; 2, 25-50%; 3, 50-75%; 4, 75-100%. Each column represents median of one to four 
sections examined on each of 5-10 mice. In almost all instances range was no greater than plus 
or minus one step on grading scale. 
Mice which received LCM  virus only and were sacrificed when moribund 6-8 
days  later  demonstrated  extensive  viral  antigen  in  the  choroid  plexus  and 
ependyma  (Fig.  3 a).  Virus  was  seen  in  the  leptomeninges  of  some  animals 
(Fig.  4  a),  and  trace  amounts  were  often  seen  in  the  olfactory  area  and  di- 
encephalon.  Other CNS structures  were virtually devoid of viral antigen. 
In adult mice inoculated i.c. with virus and then immunosuppressed with CY, 
fluorescent  viral  antigen  not  only persisted  in  choroid plexus,  ependyma,  and Fro. 3.  (a) Heavily infected choroid plexus from an adult mouse inoculated i.c. with LCM 
virus and perfused when moribund 6 days later.  Anti-LClX,I  immunofluorescent stain.  X  280. 
(b)  Similar view to show limited infection of choroid plexus in an  LCM-carrier mouse inocu- 
lated within 24 hr of birth and killed at age 8 wk.  X  280. 
866 Fla.  4.  (a) Infection of leptomeninges of cerebral cortex from an adult  mouse inoculated 
i.c.  with LCM virus and perfused when moribund 6 days later. Anti-LCM immunofluorescent 
stain.  X  280.  (b) Similar view of cerebral cortex to show absence of leptomeningeal infection 
and marked infection of cortical neurons in an LCM-carrier mouse inocu)ated within 24 hr of 
birth and killed  at age 8 wk.  5< 280. 
867 Fro.  5.  (a)  Cerebellar folium showing infection, t~robably of basket  cells, in inner half of 
molecular layer, from an adult mouse inoculated i.c. with LCM virus  (day 0), given a  single 
inoculation of C¥  (150 mg/kg) on day 3, and apparently normal when perfused on day 24. 
Anti-LCM immunofluorescent stain.  X  280.  (b)  Similar view  to  show infection  of Purkinje 
cells in an LCM-carrier mouse inoculated within 24 hr of birth and killed at age 8 wk.  X  280. 
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meninges, but gradually extended into the brain parenchyma. After 10-12 days, 
antigen was  most  frequently seen  in  areas  (cerebral cortex,  lenticulostriate, 
diencephalon) contiguous to infected membranes,  and with time (24-32 days 
after inoculation) it appeared in many parenchymal areas. Of particular note 
was  the  specific cerebellar distribution  of viral  antigen,  most  of which  was 
confined to  the  inner molecular layer  adjacent  to  Purkinje  cells  with  some 
extension into the outer molecular layer (Fig. 5 a). This suggests an association 
of viral antigen with processes of Bergmann glia, basket cells, or both (21). The 
Purkinje  cells  themselves showed minimal  evidence of infection; a  few were: 
stained in brains of mice with persistent infections of several months duration. 
Trace amounts  of  antigen were seen in  cerebellar white matter  and granule 
cells.  Viral  antigen in the brain parenchyma was usually of a finely granular 
character, contrasting with its appearance in  neonatal  carriers. 
N eonatally Inoculated Carriers 
For  comparison  with  the  CY-induced  carriers,  the  distribution  of  viral 
antigen in the CNS of neonatally inoculated carriers was also examined. Mice 
were  inoculated  i.c.  within  24  hr  of birth  and  about  80%  survived  after  a 
transient  growth-retarding  illness  (6)  during the first 3 wk  of life. As young 
adults (56-75 days of age) they were neurologically asymptomatic and free of 
histological evidence of choriomeningitis. 
Viral Antigen in Brain.--When examined as adults,  neonatally established 
carriers had brain virus titers similar to those in drug-induced carriers, but the 
appearance  and  distribution  of  antigen  were  strikingly different. There was 
only a limited infection of choroid plexus (Fig. 3 b) and of leptomeninges (Fig. 
4 b). However, parenchymal structures were far more heavily infected than in 
drug-induced carriers (Table II). Also,  infected cells had a diffuse and heavy 
burden  of antigen throughout the perikaryal cytoplasm, with little apparent 
extension into dendrites or axons (Figs. 4 b and 5 b). Another marked distinc- 
tion between the two kinds of carrier mice was the severe infection of Purkinje 
cells in animals inoculated at birth (Fig. 5 b), with very little viral antigen in 
other parts of the cerebellum (Table II). 
When mice were examined at intervals after neonatal inoculation, the pat- 
tern of infection seen in the adult appeared to be established within 1 wk. How- 
ever,  there  were  several  important  exceptions.  Antigen  appeared  slowly  in 
Purkinje cells,  so that very few were stained  7 days after infection and  this 
proportion gradually  increased  as  the  animal  matured.  In  contrast,  choroid 
plexus,  leptomeninges,  and  granule  cells  were  heavily infected  7  days  after 
inoculation with a subsequent marked decrease in the number of antigen-posi- 
tive cells (Table II). 
DISCUSSION 
Virus  Strain.--These  experiments  were  conducted  with  a  highly  neuro- 
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extraneural tissues of adult mice. This accounts for the minimal viremia in non- 
suppressed mice  (5),  and could influence the response to immunosuppression 
(13, 14, 22) as well as the distribution of infection in the brain (13). 
Induction  of Carrier State by Immunosuppression  of Adult Mice.---The  use of 
a single dose of CY to produce LCM virus-carrier infections of mice is probably 
one of the most convenient and efficient methods available. In earlier studies, 
Haas  and coworkers (23,  24)  reported that  the folic acid  antagonist,  metho- 
trexate,  produced  only  partial  and  transient  suppression  of LCM,  perhaps 
because  of  the  use  of  a  suboptimal  drug  schedule.  Hannover Larsen  (15), 
however, found that seven repeated doses of methotrexate administered over 
the first 14 days after virus injection protected all mice against LCM induced 
by the  viscerotropic Traub strain  of virus which  kills  only 70-80%  of mice 
after i.e. infection. 
Hotehin (14) reported that, when induced by X-irradiation, the carrier state 
was characterized by persistence of virus titers in brain at levels similar to those 
seen in moribund mice injected with virus  only. Our findings in  CY-treated 
mice were similar and the apparently constant titers did not reflect the con- 
tinued  spread  of  infection  in  the  CNS  as  revealed  by  immunofluorescent 
staining. 
Under  the  conditions of these  experiments,  mice receiving virus  only had 
minimal levels of viremia which were suppressed by 7 days after infection when 
animals were @ing of an acute immunopathological process, while viremia was 
regularly present on day 7 in  CY-treated mice. This underlines the  dual  role 
which the immune response can play in LCM, simultaneously inhibiting spread 
of infection and mediating disease (4, 25). 
Comparison of CNS Infections in Adult and Neonatal Virus Carriers.--Infec- 
tion in the adult carrier induced by CY is initially concentrated in membranes 
and gradually spreads to contiguous parenchyma, suggesting an age-determined 
low level of susceptibility of neurons and glia. It seems reasonable to presume 
that, in some parts  of the  CNS, unstained cells represent areas to which the 
infection has not yet extended. Differences in susceptibility between different 
types of neural cells  may account for an unusual concentration of antigen in 
basket  cell  processes  in  the  cerebellum  without  corresponding  infection  of 
juxtaposed Purkinje cells. 
Neonatally infected animals, even when examined as adults, identical in age 
with the  drug-induced carrier,  differ in several  respects.  Inoculation  shortly 
after birth results in an infection which involves many more cells. There is also 
a much heavier diffuse accumulation of antigen in the cytoplasm of individual 
cells, suggesting that there may be a difference at the cellular level in the nature 
of the persistent infection. 
Although  the  neonatal  carrier exhibits more widespread  infection in  most 
areas of the CNS, there are several exceptions, notably the minimal infection 
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(13)  and by Oldstone and Dixon (26).  One of the most obscure aspects of the 
carrier state in neonatally infected mice is the status of cells which carry little 
or no stainable  antigen, yet are  often contiguous with heavily stained  cells. 
Superficially, it seems plausible that these unstained cells  are those to which 
the infection has not yet extended. However, sequential observations indicate 
that these cells have been exposed to infectious virus over a long period,  and 
during development there  is  actually a  reduction in  antigen-positive cells  in 
choroid plexus, leptomeninges, and the internal granule cell layer. Furthermore, 
a comparison of the two types of carriers also indicates that antigen-negative 
cells are not innately resistant, since certain cells are unstained in one type of 
carrier only. 
Mims and Subrahmanyan (27) developed considerable evidence that antigen- 
negative  cells  resisted  superinfection  with  homologous virus  and  that  this 
resistance could not be attributed to interferon production by antigen-postive 
cells.  More  recently Hotchin  (28) has  described  a  similar situation in tissue 
cultures persistently infected with LCM virus in which viral antigen disappears 
from  infected  cells.  He  has  suggested  that  this  "shutdown"  phenomenon 
represents  an  abortive  replicative  cycle  of  infection  with  an  interference- 
producing  virus  subpopulation  present  in  laboratory strains  of LCM  virus. 
The  distribution of antigen in the  CNS,  although enigmatic, undoubtedly 
plays a  critical role  in the pathophysiology of acute choriomeningitis. Thus, 
adult mice dying with classical choroiditis have heavy infections of the choroid 
plexus.  Furthermore,  a  strikingly  similar  fatal  choroiditis  occurs  in  drug- 
induced carriers with extensive choroidal infections after transfer of immune 
lymphoid cells,  while neonatal carriers,  with minimal choroidal infection, fail 
to develop  acute  CNS  symptoms. These  different responses  to  adoptive im- 
munization are the subject of the following paper. 
SUMMARY 
A  single dose  of 150 mg/g of cyclophosphamide (CY),  given 3  days after 
intracerebral  (i.c.)  inoculation of lymphocytic choriomeningitis (LCM) virus, 
protected over 90%  of adult BALB/c mice against  acutely fatal choriomen- 
ingitis. Surviving mice became persistently infected carriers,  with high virus 
titers in blood and brain. 
Immunofluorescent examination  of  the  brain  showed  that  in  CY-induced 
carriers infection was initially confined to the choroid plexus, ependyma, and 
leptomeninges,  but  over  the  next  30  days  gradually  spread  to  the  neural 
parenchyma, most notably to the molecular layer of the cerebellum. By con- 
trast,  LCM  virus-carrier  mice  produced  by  neonatal  virus  injection  and 
examined as adults, showed a  much less  marked infection of choroid plexus 
and much more widespread infection of parenchyma, with a different distribu- 
tion among brain nuclei, including heavy infection of the Purkinje cells of the 
cerebellum. 872  PATHOGENESIS OF  LYMPHOCYTIC CHORIOMENINGITIS. I 
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